Table of Contents
<< Previous Issue | Jul 2012 (Vol: 2012, Issue: 7) | Next Issue >> |
- Section: Licensing
-
AstraZeneca Signs Second Licence Agreement with Rigel for Preclinical Asthma Drug
-
Roche and Seaside Therapeutics Collaborate to Develop Disease-Modifying Therapies for Neurodevelopmental Disorders
-
Ferring Licenses Late-Stage Constipation Drug from AstraZeneca Spinout Albireo
-
Russia’s SatRx Licenses Exclusive Rights to Pfizer’s DPP-IV Inhibitor
-
Evotec, Harvard and Janssen Form Three-Way Collaboration in Beta Cell Regeneration
-
Merck & Co. Strengthens its HIV Pipeline with Two Licensing Deals
-
Boehringer Ingelheim Adds Phase II Anti-Inflammatory Drug to its Respiratory Disease Pipeline
- Section: Mergers & Acquisitions
-
BMS Teams Up with AstraZeneca to Buy Amylin for US$7 B
-
GlaxoSmithKline Secures Human Genome Sciences Takeover with Sweetened Offer
- Section: Research & Development
-
Biogen Idec and Isis Pharmaceuticals Sign Second Rare Disease Option Agreement
-
AstraZeneca Signs Two Deals to Advance its Virtual Neuroscience R&D Strategy
-
Genmab Further Validates its DuoBody™ Technology with Janssen Biotech Agreement